Anti-CD19 CAR-T Cells Injection

BIOLOGICAL2 trials

Sponsors

Yan'an Affiliated Hospital of Kunming Medical University

Conditions

B Cell LymphomaB-cell Acute Lymphoblastic Leukemia

Phase 1

CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia

Yan'an Affiliated Hospital of Kunming Medical UniversityB-cell Acute Lymphoblastic Leukemia, B Cell Lymphoma

Start: 2018-08-01End: 2022-08-01Target: 10Updated: 2019-02-26

Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia

Yan'an Affiliated Hospital of Kunming Medical UniversityB-cell Acute Lymphoblastic Leukemia, B Cell Lymphoma

Start: 2020-03-15End: 2023-09-15Target: 10Updated: 2021-05-13

Related Papers

Clinical anti-lymphoma effect of T cells expressing an anti-CD19 chimeric antigen receptor in synthetic biology optimizing system.

Journal of Clinical Oncology2020-05-20